Q1 2026 Holdings
Filed 2026-05-15 | 73 holdings | $175.7M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| KLA Corporation(KLAC) | COM NEW | 482480100 | $29.3M | 19,883 | 16.7% |
| Bristol-Myers Squibb Co(BMY) | COM | 110122108 | $18.6M | 306,268 | 10.6% |
| Compass Therapeutics Inc(CMPX) | COM | 20454B104 | $7.8M | 1,465,867 | 4.4% |
| LAM Research Corporation(LRCX) | COM NEW | 512807306 | $7.7M | 36,000 | 4.4% |
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $6.8M | 210,000 | 3.9% |
| Ovintiv Inc(OVV) | COM | 69047Q102 | $6.4M | 107,500 | 3.6% |
| Intellia Therapeutics Inc(NTLA) | COM | 45826J105 | $5.7M | 445,400 | 3.3% |
| Structure Therapeutics Inc(GPCR) | SPONS ADR | 86366E106 | $4.8M | 100,000 | 2.7% |
| Solid Biosciences Inc(SLDB) | COM NEW | 83422E204 | $4.5M | 625,980 | 2.6% |
| Prothena Corp PLC(PRTA) | SHS | G72800108 | $4.4M | 449,019 | 2.5% |
| Biodesix Inc | COM | 09075X108 | $4.2M | 286,804 | 2.4% |
| Acadia Pharmaceuticals Inc(ACAD) | COM | 004225108 | $3.8M | 171,000 | 2.2% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $3.7M | 35,000 | 2.1% |
| Neurocrine Biosciences Inc(NBIX) | COM | 64125C109 | $3.6M | 27,190 | 2.0% |
| Olema Pharmaceuticals Inc(OLMA) | COM | 68062P106 | $3.3M | 219,000 | 1.9% |
| Relmada Therapeutics Inc(RLMD) | COM | 75955J402 | $2.8M | 409,387 | 1.6% |
| Ocular Therapeutix Inc(OCUL) | COM | 67576A100 | $2.7M | 320,000 | 1.5% |
| United Therapeutics Corp(UTHR) | COM | 91307C102 | $2.7M | 4,500 | 1.5% |
| Nektar Therapeutics(NKTR) | COM | 640268306 | $2.2M | 31,000 | 1.3% |
| Celldex Therapeutics Inc(CLDX) | COM NEW | 15117B202 | $2.2M | 70,095 | 1.3% |
| Novocure LTD(NVCR) | ORD SHS | G6674U108 | $2.2M | 202,330 | 1.3% |
| EQT Corporation(EQT) | COM | 26884L109 | $2.2M | 34,619 | 1.3% |
| Phathom Pharmaceuticals Inc(PHAT) | COM | 71722W107 | $2.2M | 195,000 | 1.2% |
| Bicycle Therapeutics PLC(BCYC) | SPONSORED ADS | 088786108 | $2.2M | 463,599 | 1.2% |
| Compass Pathways LTD(CMPS) | SPONSORED ADS | 20451W101 | $2.1M | 375,000 | 1.2% |
| Pacific Biosciences of California Inc(PACB) | COM | 69404D108 | $2.0M | 1,500,000 | 1.1% |
| Cytokinetics Inc(CYTK) | COM | 23282W605 | $2.0M | 30,000 | 1.1% |
| Corcept Therapeutics Inc(CORT) | COM | 218352102 | $1.9M | 47,200 | 1.1% |
| Vera Therapeutics Inc(VERA) | CL A | 92337R101 | $1.8M | 44,000 | 1.0% |
| Alkermes PLC(ALKS) | SHS | G01767105 | $1.8M | 50,000 | 1.0% |
| Engene Holdings Inc(ENGN) | COM | 29286M105 | $1.7M | 250,000 | 1.0% |
| Uniqure NV(QURE) | SHS | N90064101 | $1.6M | 100,697 | 0.9% |
| Zenas Biopharma Inc(ZBIO) | COM | 98937L105 | $1.4M | 70,000 | 0.8% |
| Quidelortho Corp | COM | 74838J101 | $1.4M | 82,548 | 0.8% |
| Foghorn Therapeutics Inc(FHTX) | COM | 344174107 | $1.3M | 281,730 | 0.8% |
| Ultragenyx Pharmaceutical Inc(RARE) | COM | 90400D108 | $1.3M | 62,000 | 0.7% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $1.2M | 21,000 | 0.7% |
| Kalvista Pharmaceuticals Inc(KALV) | COM | 483497103 | $1.1M | 57,000 | 0.7% |
| Immunome Inc(IMNM) | COM | 45257U108 | $1.1M | 50,000 | 0.6% |
| Freeport-Mcmoran CL(FCX) | CL-B | 35671D857 | $1.1M | 18,040 | 0.6% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $1.0M | 6,000 | 0.6% |
| Biogen Inc(BIIB) | COM | 09062X103 | $916.7K | 5,000 | 0.5% |
| Lipocine Inc(LPCN) | COM NEW | 53630X203 | $893.2K | 111,786 | 0.5% |
| Travere Therapeutics Inc(TVTX) | COM | 89422G107 | $867.5K | 29,200 | 0.5% |
| Harrow Health Inc(HROW) | COM | 415858109 | $846.2K | 24,000 | 0.5% |
| Pharvaris N V(PHVS) | COM | N69605108 | $843.2K | 29,847 | 0.5% |
| Verastem Inc(VSTM) | COM NEW | 92337C203 | $795.0K | 150,000 | 0.5% |
| Apogee Therapeutics Inc(APGE) | COM | 03770N101 | $757.5K | 9,000 | 0.4% |
| Halozyme Therapeutics Inc(HALO) | COM | 40637H109 | $652.8K | 10,100 | 0.4% |
| Bridgebio Pharma Inc(BBIO) | COM | 10806X102 | $645.2K | 8,688 | 0.4% |